Jaguar8 commented on a stock · Oct 24, 2024 20:47

NEWS

Precision BioSciences Receives First Approval of Clinical Trial Application to Initiate PBGENE-HBV First-In-Human Study for the Treatment of Chronic Hepatitis B

Precision BioSciences (NASDAQ: DTIL) has received its first Clinical Trial Application (CTA) approval in Moldova for PBGENE-HBV, marking the first in vivo gene editing program for chronic hepatitis B virus to enter global clinical trials. The program aims to cure chronic hepatitis B by eliminating cccDNA and inactivating integrated HBV DNA in hepatocytes using the proprietary ARCUS® platform. PBGENE-HBV delivers nuclease-encoding mRNA to the liver via lipid nanoparticles, targeting the HBV viral genome. The company is pursuing additional CTA and IND approvals globally to accelerate trial enrollment, aiming to provide a potential cure for nearly 300 million patients living with chronic hepatitis B.

Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more

Translate

Report

7680 Views

Comment

Jaguar8

Spread kindness and love. Life is short. Don’t let greed eat you.

8158

Followers

Following

93K

Visitors